FI4065176T3 - Para-aminohippurihapon (PAH) ja radioaktiivisesti merkittyjen kompleksien yhdistelmä syövän hoitoon - Google Patents

Para-aminohippurihapon (PAH) ja radioaktiivisesti merkittyjen kompleksien yhdistelmä syövän hoitoon Download PDF

Info

Publication number
FI4065176T3
FI4065176T3 FIEP21810930.4T FI21810930T FI4065176T3 FI 4065176 T3 FI4065176 T3 FI 4065176T3 FI 21810930 T FI21810930 T FI 21810930T FI 4065176 T3 FI4065176 T3 FI 4065176T3
Authority
FI
Finland
Prior art keywords
combination
use according
pah
salt
cancer
Prior art date
Application number
FIEP21810930.4T
Other languages
English (en)
Finnish (fi)
Inventor
Marian Meckel
Theresa Osl
Konstantin Zhernosekov
Original Assignee
Itm Isotope Tech Munich Se
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Itm Isotope Tech Munich Se filed Critical Itm Isotope Tech Munich Se
Application granted granted Critical
Publication of FI4065176T3 publication Critical patent/FI4065176T3/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
FIEP21810930.4T 2020-11-05 2021-11-05 Para-aminohippurihapon (PAH) ja radioaktiivisesti merkittyjen kompleksien yhdistelmä syövän hoitoon FI4065176T3 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2020/081143 WO2022096103A1 (en) 2020-11-05 2020-11-05 Combination of para-aminohippuric acid (pah) and radiolabeled complexes for treating cancer
PCT/EP2021/080822 WO2022096673A1 (en) 2020-11-05 2021-11-05 Combination of para-aminohippuric acid (pah) and radiolabeled complexes for treating cancer

Publications (1)

Publication Number Publication Date
FI4065176T3 true FI4065176T3 (fi) 2024-01-18

Family

ID=73138835

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP21810930.4T FI4065176T3 (fi) 2020-11-05 2021-11-05 Para-aminohippurihapon (PAH) ja radioaktiivisesti merkittyjen kompleksien yhdistelmä syövän hoitoon

Country Status (13)

Country Link
US (1) US20230414796A1 (cg-RX-API-DMAC7.html)
EP (1) EP4065176B1 (cg-RX-API-DMAC7.html)
JP (1) JP7531707B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230127212A (cg-RX-API-DMAC7.html)
CN (1) CN116981487A (cg-RX-API-DMAC7.html)
AU (1) AU2021375728A1 (cg-RX-API-DMAC7.html)
DK (1) DK4065176T3 (cg-RX-API-DMAC7.html)
ES (1) ES2967379T3 (cg-RX-API-DMAC7.html)
FI (1) FI4065176T3 (cg-RX-API-DMAC7.html)
HU (1) HUE065304T2 (cg-RX-API-DMAC7.html)
PL (1) PL4065176T3 (cg-RX-API-DMAC7.html)
WO (2) WO2022096103A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202304769B (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR2022007815A1 (tr) * 2022-05-13 2023-11-21 Ege Ueniversitesi Idari Ve Mali Islerdaire Bsk Yüksek stabi̇li̇teye ve radyoi̇şaretleme veri̇mi̇ne sahi̇p radyofarmasöti̇kler ve bahsedi̇len radyofarmasöti̇kleri̇ i̇çeren teranosti̇k ki̇t
CN115212322B (zh) * 2022-06-01 2024-01-16 原子高科股份有限公司 一种用于放射性药物制备的冻干药盒及其制备方法
WO2025113628A1 (en) * 2023-11-30 2025-06-05 Full-Life Technologies Hk Limited Sstr receptor targeting radio compounds and uses thereof
EP4763231A1 (en) * 2024-12-20 2026-06-24 ITM Isotope Technologies Munich SE Para-aminohippuric acid as a stabilizer in radiopharmaceutical compositions

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006176427A (ja) 2004-12-21 2006-07-06 Geno Membrane:Kk エストロン3硫酸トランスポーター活性の阻害剤
US20070025910A1 (en) 2005-07-29 2007-02-01 Norenberg Jeffrey P Anticancer therapy
US20070166774A1 (en) * 2006-01-17 2007-07-19 Groman Ernest V Functional immunoassay
CA2686933A1 (en) * 2007-04-06 2008-10-16 The Johns Hopkins University Methods and compositions for the treatment of cancer
JP5843338B2 (ja) 2011-08-05 2016-01-13 モレキュラ インサイト ファーマシューティカルズ インコーポレイテッド 放射標識された前立腺特異的膜抗原阻害剤
SMT202300035T1 (it) 2013-03-15 2023-05-12 Cancer Targeted Tech Llc Metodi per preparare agenti di pet imaging marcati con 18f indirizzati al psma e metodi diagnostici con gli stessi
EP2862857A1 (en) 2013-10-18 2015-04-22 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
AU2014336638C1 (en) 2013-10-18 2020-09-17 Novartis Ag Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
CA3060143A1 (en) 2017-05-24 2018-11-29 Itm Isotopen Technologien Munchen Ag Novel psma-binding agents and uses thereof
WO2020108753A1 (en) 2018-11-28 2020-06-04 ITM Isotopen Technologien München AG Novel tumor antigen binding agents and uses thereof
WO2020224780A1 (en) * 2019-05-08 2020-11-12 ITM Isotopen Technologien München AG Para-aminohippuric acid (pah) as a renal protective substance

Also Published As

Publication number Publication date
WO2022096103A1 (en) 2022-05-12
DK4065176T3 (da) 2024-01-02
ZA202304769B (en) 2024-10-30
PL4065176T3 (pl) 2024-03-18
AU2021375728A9 (en) 2024-06-20
CN116981487A (zh) 2023-10-31
JP7531707B2 (ja) 2024-08-09
US20230414796A1 (en) 2023-12-28
CA3171718A1 (en) 2022-05-12
ES2967379T3 (es) 2024-04-30
AU2021375728A1 (en) 2023-06-15
HUE065304T2 (hu) 2024-05-28
EP4065176A1 (en) 2022-10-05
KR20230127212A (ko) 2023-08-31
EP4065176B1 (en) 2023-10-11
JP2023547689A (ja) 2023-11-13
WO2022096673A1 (en) 2022-05-12

Similar Documents

Publication Publication Date Title
JP7358430B2 (ja) Grpr陽性ガンの検出、診断及び治療のためのgrprアンタゴニスト
US11279698B2 (en) Macrocyclic complexes of alpha-emitting radionuclides and their use in targeted radiotherapy of cancer
Sprague et al. Preparation and biological evaluation of copper-64–labeled Tyr3-octreotate using a cross-bridged macrocyclic chelator
Ramogida et al. Tumour targeting with radiometals for diagnosis and therapy
Decristoforo et al. 99mTc-HYNIC-[Tyr3]-octreotide for imaging somatostatin-receptor-positive tumors: preclinical evaluation and comparison with 111In-octreotide
Sarko et al. Bifunctional chelators in the design and application of radiopharmaceuticals for oncological diseases
JP6568618B2 (ja) 特にcck2受容体陽性腫瘍の診断および/または治療に使用するためのミニガストリン類似体
Garayoa et al. Chemical and biological characterization of new Re (CO) 3/[99mTc](CO) 3 bombesin analogues
Decristoforo et al. The influence of chelator on the pharmacokinetics of 99mTc-labelled peptides
US20230165979A1 (en) Copper-containing theragnostic compositions and methods of use
Alshoukr et al. Novel DOTA-neurotensin analogues for 111In scintigraphy and 68Ga PET imaging of neurotensin receptor-positive tumors
JP2023547689A5 (cg-RX-API-DMAC7.html)
JP2022532187A5 (cg-RX-API-DMAC7.html)
Frindel et al. Cyclam te1pa for 64Cu PET imaging. Bioconjugation to antibody, radiolabeling and preclinical application in xenografted colorectal cancer
CN118632858A (zh) 抑胃肽受体配体
IL263886B2 (en) Modified dextran conjugates containing lysine-urea-glutamate pharmacophore, methods for their preparation, preparations containing them and their uses
Morais et al. Evaluation of novel 99mTc (I)-labeled homobivalent α-melanocyte-stimulating hormone analogs for melanocortin-1 receptor targeting
Aranda-Lara et al. Improved radiopharmaceutical based on 99mTc-Bombesin–folate for breast tumour imaging
DK2795317T3 (en) Composition for use in a cancer selection method
Vats et al. 99m T c‐labeled NGR‐chlorambucil conjugate, 99m T c‐HYNIC‐CLB‐c (NGR) for targeted chemotherapy and molecular imaging
US20060188441A1 (en) Radiolabeled gallium complexes, methods for synthesis and use for PET imaging of EGFR expression in malignant tumors
Giblin et al. In vitro and in vivo evaluation of 177Lu-and 90Y-labeled E. coli heat-stable enterotoxin for specific targeting of uroguanylin receptors on human colon cancers
JP2001515494A (ja) 診断及び治療のための放射能標識したソマトスタチン受容体リガンド
Kothari et al. 99mTc (CO) 3-VIP analogues: preparation and evaluation as tumor imaging agent
Calderon et al. Synthesis of Radiolabeled Technetium-and Rhenium-Luteinizing Hormone-Releasing Hormone (99mTc/Re-Acdien-LHRH) Conjugates for Targeted Detection of Breast Cancer Cells Overexpressing the LHRH Receptor